Transcode Therapeutics (RNAZ) Share-based Compensation (2020 - 2025)
Transcode Therapeutics' (RNAZ) quarterly Share-based Compensation came in at $61865.0 in Q4 2025, down 63.34% YoY from $168770.0 in Q4 2024, and down 58.56% on a QoQ basis from $149291.0 in Q3 2025.
Transcode Therapeutics (RNAZ) Share-based Compensation (2020 - 2025) Analysis & Trends
Transcode Therapeutics (RNAZ) has 6 years of Share-based Compensation data on file, last reported at $61865.0 in Q4 2025.
- Quarterly Share-based Compensation fell 63.34% year-over-year to $61865.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $592846.0 (down 65.13% YoY) and the FY2025 annual result came in at $485428.0, down 71.45% from the prior year.
- Share-based Compensation slipped to $61865.0 in Q4 2025, from $149291.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.1 million in Q2 2024 to a low of $698.0 in Q2 2021.
- A 5-year average of $193712.1 and a median of $153510.0 in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation plunged 95.55% — and 2022, when it jumped 14025.93%.
- Tracing RNAZ's Share-based Compensation over 5 years: stood at $39000.0 in 2021, then jumped by 234.76% to $130555.0 in 2022, then soared by 137.69% to $310314.0 in 2023, then sank by 45.61% to $168770.0 in 2024, then plunged by 63.34% to $61865.0 in 2025.
- The last three Share-based Compensation figures came in at $61865.0 (Q4 2025), $149291.0 (Q3 2025), and $283614.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 61,865.00 |
| Dec 31, 2025 | 61,865.00 |
| Sep 30, 2025 | 149,291.00 |
| Sep 30, 2025 | 149,291.00 |
| Jun 30, 2025 | 283,614.00 |
| Jun 30, 2025 | 283,614.00 |
| Mar 31, 2025 | 157,729.00 |
| Mar 31, 2025 | 157,729.00 |
| Dec 31, 2024 | 168,770.00 |
| Dec 31, 2024 | 168,770.00 |
| Sep 30, 2024 | 204,482.00 |
| Sep 30, 2024 | 204,482.00 |
| Jun 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 183,152.00 |
| Mar 31, 2024 | 183,152.00 |
| Dec 31, 2023 | 310,314.00 |
| Dec 31, 2023 | 310,314.00 |
| Sep 30, 2023 | 392,331.00 |
| Sep 30, 2023 | 392,331.00 |